How COVID is Evolving Participation in Research Studies
Made with Visme Infographic Maker Read More…
Bill Nye the Science Guy is speaking at the 2024 Annual Ataxia Conference! Register now. LEARN MORE!
Made with Visme Infographic Maker Read More…
NAF is proud to feature Felicia Williams as a recipient of NAF’s 2020 Diverse Scientists in Ataxia Pre-Doctoral Research Fellowship. Felicia developed a new method to identify genes that suppress protein clumping. Bio: Felicia Williams graduated from the University of Georgia in 2019 where she studied genetics and biotechnology. Here Read More…
Let’s chat about Clinical Trial Readiness with a focus on Ataxia. Clinical trials ensure that treatments are safe and effective before they gain approval for widespread use in humans. Clinical trials test new treatments and therapies including: new drugs, different use for an already approved drug, medical devices, new treatment/therapy Read More…
What does a placebo mean? A placebo is a simulated substance that has no therapeutic effect or active ingredients. Often, a placebo looks, feels, and tastes like other therapies being tested in the clinical trial. What is the placebo effect, and why is it important? https://www.youtube.com/watch?v=5RhG_ySxhDA Why are placebo-controlled trials Read More…
Author: Sue Hagen, Research Services Director I recently attended the virtual annual meeting of the Drug Information Association. I took in four days of sessions, all relating to topics of interest to all stakeholders involved in drug discovery and development. My head is still spinning! While you would think that Read More…
What is an Informed Consent Form (ICF)? Informed Consent Forms are important aspect of a clinical trial. An ICF is a document that provides a potential clinical trial participant information about the clinical trial and any risks there may be in participating. The goal behind the ICF is to present Read More…
NAF is committed to providing the resources to fund research needed to develop treatments and therapies for people with Ataxia. We fund research studies ranging from $35,000-$100,000 per study. We are accepting Letters of Intent for research grants through late September and early October on proposalCENTRAL. For more information visit www.ataxia.org/researcher-resources. If you Read More…
Guest Authors: Drs. Paulson, Ashizawa, and Öz Right now, it’s an exciting time in the Ataxia field. Many companies are working rapidly to bring therapies to the clinic for the Spinocerebellar Ataxias (SCAs). Unfortunately, however, we still need to know more about the natural history of SCA and relevant biomarkers Read More…
Author: Sue Hagen, Research Services Director In the 14 years that I have been on staff at the National Ataxia Foundation, I have heard many times that clinical trials for therapy development for Ataxia will start within the next 5 years. And I have seen the Ataxia community patiently and Read More…
Guest Author: Sam Kirton, NAF Board of Directors President Fighting Ataxia is a cause that is close to Sam Kirton’s heart. He lost several family members to the disease. He volunteers his time to help make sure that NAF continues to move boldly forward, championing efforts to accelerate development of Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.